Cloning | Jotup

Global Stem Cell Manufacturing Market (2021 to 2026) - Supportive Regulatory Framework Across Developing Countries Presents Opportunities - ResearchAndMarkets.com

Retrieved on:

Thursday, May 27, 2021

Biotechnology, Health, Stem cells, Branches of biology, Articles, Biology, Stem cells, Induced stem cells, Biotechnology, Cell biology, Cloning, Science, technology, engineering, and mathematics, Stem-cell line, Agilent Technologies, Stem-cell therapy

The Global Stem Cell Manufacturing Market is projected to reach USD 18 billion by 2026 from USD 11.5 billion in 2021, at a CAGR of 9.4% during the forecast period.

Key Points:

The Global Stem Cell Manufacturing Market is projected to reach USD 18 billion by 2026 from USD 11.5 billion in 2021, at a CAGR of 9.4% during the forecast period.
The Stem Cell Manufacturing market by product is categorized into consumables, instruments, and stem cell lines.
The large share of this segment can be attributed to the frequent purchase of consumables, rising stem cell research, and increasing demand for stem cell therapies.
North America accounted for the largest share of the Stem Cell Manufacturing market.

Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences

Retrieved on:

Tuesday, May 25, 2021

A replay of the presentations will be posted on the Frequency website following the event.

Key Points:

A replay of the presentations will be posted on the Frequency website following the event.
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.
The Companys progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies.
The Companys lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function.

Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs

Retrieved on:

Tuesday, May 18, 2021

Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Emerging technologies, Stem cells, Cloning, Regenerative medicine, Susan L. Solomon, Center for Stem Cell and Regenerative Medicine

b'MIAMI, May 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.\nDr.

Key Points:

b'MIAMI, May 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.\nDr.
Gincel brings over 20 years of leadership experience overseeing development and commercialization of regenerative medicines, including cell and gene therapies, as well as establishing public-private collaborations and corporate partnerships.
Additionally, he served as Executive Director at the Maryland Stem Cell Research Fund (MSCRF), where he managed over $150+ million in stem cell research funding.
During his tenure, he helped create and support more than 55 technology startup companies with over $120 million of follow-on funding and numerous successful exits.

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May

Retrieved on:

Friday, May 14, 2021

Biotechnology, General Health, Health, Pharmaceutical, Oncology, Life sciences, Biology, Branches of biology, Biotechnology, Stem cells, Cell biology, Cloning, Biopharmaceutical, Hematopoietic stem cell transplantation

b'Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:\nCowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET\nOppenheimer Rare & Orphan Disease Summit on Friday, May 21, at 2:55 p.m. ET\nLive webcasts of the fireside chats can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .

Key Points:

b'Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:\nCowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET\nOppenheimer Rare & Orphan Disease Summit on Friday, May 21, at 2:55 p.m. ET\nLive webcasts of the fireside chats can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .
The webcast replays will be available for 90 days following each event.\nMagenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.
Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.\nMagenta is based in Cambridge, Mass.
For more information, please visit www.magentatx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005057/en/\n'

Therapeutic Solutions International Subsidiary Campbell Neurosciences Reports Positive Preclinical Data in Animal Model of Schizophrenia Using Proprietary Universal Donor Mesenchymal Stem Cell

Retrieved on:

Monday, May 10, 2021

Branches of biology, Biology, Life sciences, Biotechnology, Induced stem cells, Cell biology, Cloning, Developmental biology, Stem cell

"Our data suggests similar effects may be induced by stem cell administration, which appears to possess a significantly superior safety profile than giving patients shocks with ultra-high voltage.

Key Points:

"Our data suggests similar effects may be induced by stem cell administration, which appears to possess a significantly superior safety profile than giving patients shocks with ultra-high voltage.
"\nSchizophrenics appears to possess an immunological component given the abnormal inflammation and immune response skewing that occurs in these patients in the brain and the periphery.
This will allow us to file and clear multiple INDs," said Timothy Dixon, President and CEO of Therapeutic Solutions International and Founder of Campbell Neurosciences.
"We are encouraged and excited by the great support we have been having in providing the first stem cell based approach for mental illness.

HealthLynked Releases Recent "Future of Healthcare" Summit in Virtual Format

Retrieved on:

Thursday, May 6, 2021

Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Cloning, Developmental biology, Stem cell

The virtual summit featured twenty-nine lectures from leading experts in their fields covering: stem cells, regenerative medicine, anti-aging, cancer diagnosis, artificial intelligence, and advanced DNA testing.

Key Points:

The virtual summit featured twenty-nine lectures from leading experts in their fields covering: stem cells, regenerative medicine, anti-aging, cancer diagnosis, artificial intelligence, and advanced DNA testing.
Registration for the virtual summit is only $49.99.\nDr.
Michael Dent, CEO of HealthLynked stated, "The Future of Healthcare Summit was a huge success and the feedback we have received on the lectures and content has been exceptional.
The Virtual Summit was created to make the event available to a much larger audience.

Codex DNA Releases Long Gene Fragment Cloning On The BioXp™ System

Retrieved on:

Tuesday, May 4, 2021

Branches of biology, Biology, Life sciences, Molecular biology, Molecular genetics, Biotechnology, Artificial gene synthesis, XC2, DNA, Cloning, Synthetic biology, Molecular cloning

b'San Diego, CA, May 04, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc., creators of the BioXp\xe2\x84\xa2 system, a fully automated benchtop instrument that enables\xc2\xa0numerous\xc2\xa0synthetic biology workflows, announced the addition of longer fragment cloning to the BioXp\xe2\x84\xa2 system.

Key Points:

b'San Diego, CA, May 04, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc., creators of the BioXp\xe2\x84\xa2 system, a fully automated benchtop instrument that enables\xc2\xa0numerous\xc2\xa0synthetic biology workflows, announced the addition of longer fragment cloning to the BioXp\xe2\x84\xa2 system.
Scientists are now able to produce error-corrected, multivariant, de novo synthetic genes up to 7.2 kilobase pairs (kb) in length, and clone them into custom vectors hands-free and overnight, using the company\xe2\x80\x99s Gibson Assembly\xc2\xae technology.\n\xe2\x80\x9cWe\xe2\x80\x99ve developed a process for automated synthesis of long gene fragment cloning using the BioXp\xe2\x84\xa2 system.
This enables our customers to create error-corrected genes at a faster rate while eliminating the need to synthesize them manually or through outsourcing,\xe2\x80\x9d said Todd R. Nelson, PhD, Chief Executive Officer of Codex DNA.
Codex DNA is accelerating advances in the fields of personalized medicine, antibody engineering, vaccine development, drug discovery, and DNA storage.\n'

Brian C. Handerhan, MBA, takes on the newly created role of Vice President, Operations for Cell X Technologies, Inc.

Retrieved on:

Monday, May 3, 2021

Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Developmental biology, Cloning, Progenitor cell

b'CLEVELAND, May 3, 2021 /PRNewswire/ -- Cell X Technologies\' CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA,who will take on the newly created position of Vice President, Operations.

Key Points:

b'CLEVELAND, May 3, 2021 /PRNewswire/ -- Cell X Technologies\' CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA,who will take on the newly created position of Vice President, Operations.
"\nFounded in 2017, Cell X Technologies, Inc. develops and provides equipment, software, and process management tools to support stem cell research and bio-fabrication.The company\'s Cell X Platform is the only end-to-end fully robotic culture automation and analysis system whose applications span the entire development pipeline for cell therapies.
Designed to remove time-consuming and costly effects of technician and process variability in cell product development, Cell X leverages advanced image analytics and precision automation to improve decision making, productivity and documentation.
Cell X Technologies is committed to contributing to the ongoing transformation of stem and other progenitor cell biology into safe, effective, and affordable diagnostics and therapeutic procedures that improve all of our lives.

FDA Authorizes Novel Stem Cell Trial for Parkinson’s

Retrieved on:

Wednesday, April 28, 2021

Research, FDA, Genetics, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Science, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Mesenchymal stem cell, Cell therapy

b'Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson\xe2\x80\x99s Disease.\nThe trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson\xe2\x80\x99s patients in such high quantities over repeat treatments.

Key Points:

b'Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson\xe2\x80\x99s Disease.\nThe trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson\xe2\x80\x99s patients in such high quantities over repeat treatments.
Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each.\n\xe2\x80\x9cThis is our third FDA-authorized study for Parkinson\xe2\x80\x99s,\xe2\x80\x9d elaborates HBSCRF Founder Donna Chang.
From those, we gained an idea of what doses and periodicity of stem cell yielded dramatic results, and so were able to design this larger clinical trial very deliberately.
\xe2\x80\x9cWe have finally overcome the major hurdles of cell therapy.

One World Pharma Announces First Sale of Cuttings in Colombia

Retrieved on:

Monday, April 26, 2021

Asexual reproduction, Cloning, Cutting, Plant reproduction, OWP, XC2, Biology, Branches of biology, Articles

The ability to sell cuttings is mutually advantageous to OWP\xe2\x80\x99s customers and the Company.\xc2\xa0 While many cultivators prefer and are comfortable with purchasing and planting seeds, many would prefer the time-to-market advantage and elimination of germination risk by buying plantlets.

Key Points:

The ability to sell cuttings is mutually advantageous to OWP\xe2\x80\x99s customers and the Company.\xc2\xa0 While many cultivators prefer and are comfortable with purchasing and planting seeds, many would prefer the time-to-market advantage and elimination of germination risk by buying plantlets.
One World Pharma has developed an effective means by which to grow genetically superior cuttings at scale.\nTo that end, OWP cuttings can be grown in a 20 day cycle with a current capacity of approximately 9,000 per cycle, with an expected scaling to a capacity of 18,000 cuttings per cycle by year end.\nThis new ICA approval builds on previous CBD and THC strain approvals and is an effective confirmation of the importance of the Company\xe2\x80\x99s seed license.
OWP offers a reliable and sustainable supply chain for chemical formulators, food & beverage producers as well as beauty product manufacturers worldwide.
The company maintains corporate offices in Las Vegas, NV and Bogota Colombia and a facility in Popayan, Colombia.\n'